Tralokinumab for uncontrolled asthma

Antohe, Ileana; Croitoru, Rodica; Antoniu, Sabina A

doi:10.1517/14712598.2012.748740

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL‐13 also causes mucus production, goblet cell hyperplasia, airway hyper‐responsiveness, myofibroblast differentiation, contractility of smooth muscle cells, and airway remodeling. The latter is believed to rely, among others, on the IL‐13‐mediated periostin secretion by bronchial epithelial cells, with periostin exerting paracrine effects on fibroblasts leading to airway remodeling , perhaps explaining the role of IL‐13 in corticosteroid‐resistant asthma . IL‐13‐targeting biologicals encompass several anti‐IL‐13 mAbs, including ABT‐308, anrukinzumab, IMA‐026, lebrikizumab, CNTO‐5825, GSK679586, QAX576, and tralokinumab.…”

Section: Overview Of Biologicals Used For Allergic and Urticarial Dismentioning

confidence: 99%

“…The most frequent AEs with the use of tralokinumab in patients with moderate‐to‐severe asthma were injection site reaction (10/146), increase in asthma symptoms or asthma exacerbation (16/146), headache (13/146), nasopharyngitis (10/146), diarrhea (5/146), urinary tract infections (6/146), and transient slight increase in blood eosinophil counts (4/146) . No SAEs were observed .…”

Section: Adverse Eventsmentioning

confidence: 99%

See 1 more Smart Citation

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Boyman

Kaegi

Akdiş

et al. 2015

Allergy

100

View full text Add to dashboard Cite

Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune-mediated disorders. Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)-type and Th2-promoting cytokines, including interleukin-4 (IL-4), IL-5, IL-9, IL-13, IL-31, and thymic stromal lymphopoietin (TSLP); pro-inflammatory cytokines, such as IL-1b, IL-12, IL-17A, IL-17F, IL-23, and tumor necrosis factor (TNF); chemokine receptor CCR4; and lymphocyte surface and adhesion molecules, including CD2, CD11a, CD20, CD25, CD52, and OX40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.Abbreviations ABPA, allergic bronchopulmonary aspergillosis; ACQ-5/ACQ-6/ACQ-7, 5-item/6-item/7-item

show abstract

Section: Overview Of Biologicals Used For Allergic and Urticarial Dismentioning

confidence: 99%

Section: Adverse Eventsmentioning

confidence: 99%

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Boyman

Kaegi

Akdiş

et al. 2015

Allergy

100

View full text Add to dashboard Cite

show abstract

“…Tralokinumab is a human IgG4 anti IL-13 monoclonal antibody which is effective in a subset of asthma patients characterized by the highest sputum IL-13 levels (Antohe et al 2013). In phase 2b study, tralokinumab regimens had an acceptable safety and tolerability profile, but did not significantly reduce asthma exacerbation rates in patients with severe uncontrolled asthma.…”

Section: Anrukinzumab/lebrikizumab/ Tralokinumabmentioning

confidence: 99%

Monoclonal Antibodies for the Management of Severe Asthma

Rubinsztajn

Chazan

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Asthma is a heterogeneous inflammatory disease. Most patients respond to current standard of care, i.e., bronchodilators, inhaled glucocorticosteroids and other anti-inflammatory drugs, but in some adequate asthma control cannot be achieved with standard treatments. These difficult-to-treat patients would be the target population for new biological therapies. At present, omalizumab is the only biological agent approved for the treatment of early-onset, severe IgE-dependent asthma. It is safe, effective, and well tolerated. Also, discovery of asthma subtypes suggests new treatments. Half of patients with severe asthma have T-helper type 2 (Th-2) inflammation and they are expected to benefit from monoclonal antibody-based treatments. The efficacy of the investigational monoclonal antibody mepolizumab which targets IL-5 has been well documented in late onset non-atopic asthma with persistent eosinophilic airway inflammation. Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development. In clinical trials, these drugs reduce disease activity and improve lung function, asthma symptoms, and quality of life. However, studies on larger groups of patients are needed to confirm their safety and efficacy.

show abstract